FCGR3A and acute myeloid leukemia: To enable therapeutic activity, the number of CD16A+ NK cells in patients needs to be sufficiently high in addition to retained ADCC functionality; the latter may indeed be the case in the majority of patients with AML reported to be positive for CD16A and responsive to CD16A engagement at diagnosis and after chemotherapy29–31.